GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Operating Income

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Operating Income : ¥-295.2 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Operating Income?

Suzhou Zelgen Biopharmaceuticals Co's Operating Income for the three months ended in Jun. 2024 was ¥-41.9 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-295.2 Mil.

Warning Sign:

Suzhou Zelgen Biopharmaceuticals Co Ltd has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Suzhou Zelgen Biopharmaceuticals Co's Operating Income for the three months ended in Jun. 2024 was ¥-41.9 Mil. Suzhou Zelgen Biopharmaceuticals Co's Revenue for the three months ended in Jun. 2024 was ¥132.5 Mil. Therefore, Suzhou Zelgen Biopharmaceuticals Co's Operating Margin % for the quarter that ended in Jun. 2024 was -31.64%.

Suzhou Zelgen Biopharmaceuticals Co's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Suzhou Zelgen Biopharmaceuticals Co's annualized ROC % for the quarter that ended in Jun. 2024 was -12.16%. Suzhou Zelgen Biopharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -28.33%.


Suzhou Zelgen Biopharmaceuticals Co Operating Income Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Operating Income Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial -440.27 -358.04 -502.63 -503.82 -325.72

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.17 -106.75 -91.55 -55.00 -41.91

Suzhou Zelgen Biopharmaceuticals Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-295.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Suzhou Zelgen Biopharmaceuticals Co  (SHSE:688266) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Suzhou Zelgen Biopharmaceuticals Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-167.64 * ( 1 - 2.87% )/( (1351.753 + 1326.28)/ 2 )
=-162.828732/1339.0165
=-12.16 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3104.748 - 238.191 - ( 2414.896 - max(0, 1208.19 - 2722.994+2414.896))
=1351.753

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3099.663 - 236.774 - ( 2376.508 - max(0, 1169.133 - 2705.742+2376.508))
=1326.28

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Suzhou Zelgen Biopharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-102.144/( ( (292.107 + max(56.985, 0)) + (293.845 + max(78.125, 0)) )/ 2 )
=-102.144/( ( 349.092 + 371.97 )/ 2 )
=-102.144/360.531
=-28.33 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(112.023 + 130.431 + 55.417) - (238.191 + 0 + 2.6950000000002)
=56.985

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(130.88 + 141.123 + 47.871000000001) - (236.774 + 0 + 4.9750000000001)
=78.125

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Suzhou Zelgen Biopharmaceuticals Co's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-41.91/132.452
=-31.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Suzhou Zelgen Biopharmaceuticals Co Operating Income Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Zelgen Biopharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Executives
Zhang Bin Core technical personnel
Huang Gang senior management
Lv Bin Hua Directors, senior managers, core technical personn
Lu Hui Ping Directors, senior managers
Gao Qing Ping senior management
Wu Ji Sheng Directors, senior managers, core technical personn
Zhang Jun Li senior management
Wu Li Qing Core technical personnel
Core technical personnel
Sheng Ze Lin Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co Headlines

No Headlines